Clinical course and prognostic factors of children with Burkitt’s lymphoma in a developing country: the experience of a single centre in Brazil with the use of MTX at a dose of 0.5 g/m2, because only two patients relapsed and the other ten died of infectious or metabolic complications before or at the beginning of treatment. In African countries, the limited availability of drugs, insufficient supportive measures, low social and cultural levels, distance from the referral hospital, and political instability have an adverse impact on patient compliance and inevitably on the outcome of treatment(29). The survival of children with B-cell NHL living in these regions ranges from 50.5% to 79% depending on the intensity of treatment(3). Although the overall outcomes do not compare with the experience of centers in Europe and the US using more intensive regimens, the results remain impressive. It is noteworthy that some of these countries provided a minimum of therapy such as cyclophosphamide monotherapy(26). This also underscores the need to fully understand biological and socioeconomic differences within the same disease group in an attempt to tailor therapy and minimize toxicity. It is possible that the poorer outcome in underdeveloped nations is not just a reflection of socioeconomic factors, but also of unique biological differences. It becomes increasingly clear that understanding the molecular and genetic signatures of NHL-B can lead to novel therapies and better survival(30). Conclusion Our findings confirm a favorable prognosis for a significant number of children who are survivors of BL after treatment with an intermediate dose of MTX. The challenge remains to identify those patients who are at a higher risk of relapsing, because they may require more aggressive therapy. In countries with limited resources, the challenge is to plan treatment intensity so that morbidity is manageable, without significantly decreasing the survival rate. The observation of a significantly lower survival in children and adolescents with uric acid concentrations of 7 mg/dL or higher at diagnosis is also very interesting, suggesting that the concentration of the metabolite may be a good marker of tumor burden, but further studies are needed to corroborate this finding. Acknowledgements The authors wish to thank FAPEMIG for a grant to ACSCG, a medical student. MBV is a level 2 CNPq researcher. References 1. Cairo MS, Raetz E, Lim MS, Davenport V, Perkins SL. Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future. Pediatr Blood Cancer. 2005;45(6):753-69. 2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pieleri SA, Stein H, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. (IARC WHO Classification of tumours, n.2). 3. Traoré F, Coze C, Atteby JJ, André N, Moreira C, Doumbe P, et al. Cyclophosphamide monotherapy in children with Burkitt lymphoma: a study from the French-African Pediatric Oncology Group (GFAOP). Pediatr Blood Cancer. 2011;56(1):70-6. 4. Ferry JA. Burkitt’s lymphoma: clinicopathologic features and differential diagnosis. Oncologist. 2006;11(4):375-83. Rev Bras Hematol Hemoter. 2012;34(5):361-6 5. Toren A, Mandel M, Shahar E, Rimmoni E, Roizin H, Neuman Y, et al. Primary central nervous system Burkitt’s lymphoma presenting as Guillain-Barre syndrome. Med Pediatr Oncol. 1994;23(4):372-5. 6. Kelly GL, Rickinson AB. Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. Hematology Am Soc Hematol Educ Program 2007:277-84. 7. Ribeiro RC, Sandlund JT. Burkitt lymphoma in African children: a priority for the global health agenda? Pediatr Blood Cancer. 2008;50(6):1125-6. 8. Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A; BFM Group. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105(3):948-58. 9. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, Weston C, Perkins SL, Raphael M, McCarthy K, Patte C; FAB LMB96 International Study Committee. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109(7):2736-43. 10. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7(3):332-9. 11. Monteiro CA. Critérios antropométricos no diagnóstico da desnutrição em programas de assistência à criança. Rev Saúde Pública 1984;18(3):209-17. 12. Wollner N, Wachtel AE, Exelby PR, Centore D. Improved prognosis in children with intra-abdominal non-Hodgkin’s lymphoma following LSA2L2 protocol chemotherapy. Cancer. 1980;45(12):3034-9. 13. Reiter A, Schrappe M, Ludwig WD, Lampert F, Harbott J, Henze G, et al. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood. 1992;80(10):2471-8. 14. kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457-81. 15. Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, Lutz P, Coze C, Perel Y, Raphaël M, Terrier-Lacombe MJ; Société Française d’Oncologie Pédiatrique. The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97(11):3370-9. 16. Burkhardt B, Zimmermann M, Oschlies I, Niggli F, Mann G, Parwaresch R, Riehm H, Schrappe M, Reiter A; BFM Group. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131(1):39-49 17. Klumb CE, Schramm MT, De Resende LM, Carriço MK, Coelho AM, de Meis E, et al. Treatment of children with B-cell non-Hodgkin’s lymphoma in developing countries: the experience of a single center in Brazil. J Pediatr Hematol Oncol. 2004;26(7):462-8. 18. Muwakkit SA, Razzouk BI, Shabb NS, Hancock ML, Dabbous I, Firzli S, et al. Clinical presentation and treatment outcome of children with Burkitt lymphoma in Lebanon: a single institution’s experience. J Pediatr Hematol Oncol. 2004;26(11):749-53. 19. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, Weston C, Raphael M, Perkins SL, McCarthy K, Cairo MS; FAB/LMB96 International Study Committee. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109(7):2773-80. 365